HER2-positive gastroesophageal junction adenocarcinoma
Clinical trials for HER2-positive gastroesophageal junction adenocarcinoma explained in plain language.
Never miss a new study
Get alerted when new HER2-positive gastroesophageal junction adenocarcinoma trials appear
Sign up with your email to follow new studies for HER2-positive gastroesophageal junction adenocarcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for stomach cancer: targeted drug combo trial launches
Disease control OngoingThis study tests a drug called trastuzumab deruxtecan (T-DXd), alone or with chemotherapy and immunotherapy, in people with advanced HER2-positive stomach or esophageal cancer. The goal is to see if these combinations are safe and can shrink tumors. About 450 adults with cancer t…
Matched conditions: HER2-POSITIVE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug under Real-World watch for tough stomach cancer
Disease control OngoingThis study follows about 257 adults with advanced HER2-positive stomach or gastroesophageal junction cancer who have already tried a trastuzumab-based treatment. Researchers will track how well the drug trastuzumab deruxtecan (T-DXd) works in everyday medical practice, including …
Matched conditions: HER2-POSITIVE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC